TOPOTECAN/IFOSFAMIDE THERAPY FOR RELAPSED/REFRACTORY PEDIATRIC SOLID TUMORS

被引：0
|
作者：
Sugiyama, Masanaka [1 ]
Arakawa, Ayumu [1 ,2 ]
Watanabe, Yuko [1 ]
Nakajima, Miho [1 ]
Tanimura, Kazuki [1 ]
Uchida, Eriko [1 ]
Tao, Kayoko [1 ]
Yoneda, Akihiro [3 ]
Kawai, Akira [4 ]
Ogawa, Chitose [1 ,2 ]
机构：
[1] Natl Canc Ctr, Dept Pediat Oncol, Tokyo, Japan
[2] Natl Canc Ctr, Rare Canc Ctr, Tokyo, Japan
[3] Natl Canc Ctr, Dept Pediat Surg Oncol, Tokyo, Japan
[4] Natl Canc Ctr, Dept Musculoskeletal Oncol & Rehabil, Tokyo, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2024年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OS7-5
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [31] Phase I Clinical Trial of Ifosfamide, Oxaliplatin, and Etoposide (IOE) in Pediatric Patients With Refractory Solid Tumors
    Lam, Catherine G.
    Furman, Wayne L.
    Wang, Chong
    Spunt, Sheri L.
    Wu, Jianrong
    Ivy, Percy
    Santana, Victor M.
    McGregor, Lisa M.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2015, 37 (01) : E13 - E18
  • [32] A phase I study of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.
    McGregor, L. M.
    Spunt, S. L.
    Ward, D.
    Wu, J.
    Billups, C.
    Ivy, S. P.
    Santana, V. M.
    Fouladi, M.
    Furman, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Temozolomide in resistant or relapsed pediatric solid tumors
    De Sio, L.
    Milano, G. M.
    Castellano, A.
    Jenkner, A.
    Fidani, P.
    Dominici, C.
    Donfrancesco, A.
    PEDIATRIC BLOOD & CANCER, 2006, 47 (01) : 30 - 36
  • [34] Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
    Meany, Holly Jane
    Dome, Jeffrey
    Hinds, Pamela S.
    Bagatell, Rochelle
    Shusterman, Suzanne
    Widemann, Brigitte C.
    Stern, Emily
    London, Wendy B.
    Kim, AeRang
    Fox, Elizabeth
    Rodriguez-Galindo, Carlos
    Minturn, Jane E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience
    Bay, Sema Bueyukkapu
    Kebudi, Rejin
    Gorgun, Omer
    Zulfikar, Buelent
    Darendeliler, Emin
    Cakir, Fatma B.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (06) : 1343 - 1348
  • [36] Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A pediatric oncology group phase II study
    Saylors, RL
    Stine, KC
    Sullivan, J
    Kepner, JL
    Wall, DA
    Bernstein, ML
    Harris, MB
    Hayashi, R
    Vietti, TJ
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) : 3463 - 3469
  • [37] ETOPOSIDE AND ETOPOSIDE IFOSFAMIDE THERAPY FOR REFRACTORY TESTICULAR-TUMORS
    BREMER, K
    NIEDERLE, N
    KRISCHKE, W
    HIGI, M
    SCHEULEN, ME
    SCHMIDT, CG
    SEEBER, S
    CANCER TREATMENT REVIEWS, 1982, 9 : 79 - 84
  • [38] Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma
    Voloschin, Alfredo D.
    Betensky, Rebecca
    Wen, Patrick Y.
    Hochberg, Fred
    Batchelor, Tracy
    JOURNAL OF NEURO-ONCOLOGY, 2008, 86 (02) : 211 - 215
  • [39] Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study
    Hawkins, Douglas S.
    Bradfield, Scott
    Whitlock, James A.
    Krailo, Mark
    Franklin, Janet
    Blaney, Susan M.
    Adamson, Peter C.
    Reaman, Gregory
    PEDIATRIC BLOOD & CANCER, 2006, 47 (06) : 790 - 794
  • [40] Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma
    Alfredo D. Voloschin
    Rebecca Betensky
    Patrick Y. Wen
    Fred Hochberg
    Tracy Batchelor
    Journal of Neuro-Oncology, 2008, 86 : 211 - 215
12345